By successfully encapsulating a vaccine into a spider silk microparticle, Swiss and German researchers have discovered a novel technique that will help fight cancer and certain infectious diseases.
To fight cancer, researchers increasingly use vaccines that stimulate the immune system to identify and destroy tumour cells. However, the desired immune response is is not always guaranteed. In order to strengthen the efficacy of vaccines on the immune system – and in particular on T lymphocytes, specialized in the detection of cancer cells – researchers from the universities of Geneva (UNIGE), Freiburg (UNIFR), Munich, and Bayreuth, in collaboration with the German company AMSilk, have developed spider silk microcapsules capable of delivering the vaccine directly to the heart of immune cells. This process, published in the journal Biomaterials, could also be applied to preventive vaccines to protect against infectious diseases, and constitutes an important step towards vaccines that are stable, easy to use, and resistant to the most extreme storage conditions.
Our immune system is largely based on two types of cells: B lymphocytes, which produce the antibodies needed to defend against various infections, and T lymphocytes. In the case of cancer and certain infectious diseases such as tuberculosis, T lymphocytes need to be stimulated. However, their activation mechanism is more complex than that of B lymphocytes: to trigger a response, it is necessary to use a peptide, a small piece of protein which, if injected alone, is rapidly degraded by the body even before reaching its target.
“To develop immunotherapeutic drugs effective against cancer, it is essential to generate a significant response of T lymphocytes,» says Professor Carole Bourquin, a specialist in antitumor immunotherapies at the faculties of medicine and science of the UNIGE, who directed this work. “As the current vaccines have only limited action on T-cells, it is crucial to develop other vaccination procedures to overcome this issue.”
A virtually indestructible capsule
Scientists used synthetic spider silk biopolymers—a lightweight, biocompatible, non-toxic material that is highly resistant to degradation from light and heat. “We recreated this special silk in the lab to insert a peptide with vaccine properties,» explains Thomas Scheibel, a world specialist of spider silk from the University of Bayreuth who participated in the study. “The resulting protein chains are then salted out to form injectable microparticles.”
Silk microparticles form a transport capsule that protects the vaccine peptide from rapid degradation in the body, and delivers the peptide to the center of the lymph node cells, thereby considerably increasing T lymphocyte immune responses. “Our study has proved the validity of our technique”, reveals Carole Bourquin. “We have demonstrated the effectiveness of a new vaccination strategy that is extremely stable, easy to manufacture and easily customizable.”
Towards a new vaccine model
The synthetic silk biopolymer particles demonstrate a high resistance to heat, withstanding over 100°C for several hours without damage. In theory, this process would make it possible to develop vaccines that do not require adjuvants and cold chains. An undeniable advantage, especially in developing countries where one of the great difficulties is the preservation of vaccines. One of the limitations of this process, however, is the size of the microparticles: while the concept is in principle applicable to any peptide, which are all small enough to be incorporated into silk proteins, further research is needed to see if it is also possible to incorporate the larger antigens used in standard vaccines, especially against viral diseases.
When science imitates nature
“More and more, scientists are trying to imitate nature in what it does best”, adds Scheibel. “This approach even has a name: bioinspiration, which is exactly what we have done here.” The properties of spider silk make it a particularly interesting product: biocompatible, solid, thin, biodegradable, resistant to extreme conditions and even antibacterial, one can imagine multiple applications, including wound dressings or sutures.
Learn more: A new kind of vaccine based on spider silk
The Latest on: Vaccine delivery
[google_news title=”” keyword=”vaccine delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine delivery
- Cancer Vaccine Triggers Fierce Immune Response to Fight Malignant Brain Tumors in Human Patientson May 11, 2024 at 6:37 am
In the first human trial, an mRNA cancer vaccine at the University of Florida triggered immune systems to fiercely attack glioblastoma.
- Revolutionary mRNA Cancer Vaccine Shows Immense Promise in First-Ever Human Clinical Trialon May 10, 2024 at 8:56 am
In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine created at the University of Florida rapidly reprogrammed the immune system to target glioblastoma, the deadliest ...
- Researchers develop mRNA vaccine to target aggressive brain canceron May 9, 2024 at 10:30 pm
Researchers from the University of Florida in the US developed an mRNA cancer vaccine which triggers the immune system to target the tumour. Approximately 19,000 individuals in th ...
- The WHO’s naive global vaccine plan won’t withstand contact with realityon May 9, 2024 at 11:39 am
The AstraZeneca vaccine was, for a while, the most celebrated product in Britain. The UK was one of only a handful of countries with the skills and apparatus not just to invent an effective Covid jab ...
- New mRNA vaccine for deadly brain cancer triggers a strong immune responseon May 9, 2024 at 4:00 am
And because mRNA can be isolated, amplified, and packaged for delivery within a matter of days, these tailored vaccines can be generated in about a month. Sayour and other researchers hypothesize that ...
- Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogson May 7, 2024 at 2:29 am
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.
- Global Vaccine Delivery Devices Market Report 2024-2032: Device, Route of Administration, End User, and Regional Analysis and Forecastson May 7, 2024 at 2:25 am
The "Global Vaccine Delivery Devices Market Report by Device, Route of Administration, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global vaccine ...
- mRNA vaccine tackles deadly brain cancer in human trialon May 6, 2024 at 6:45 am
Glioblastoma is one of the most deadly cancers, with few treatment options available. Now, a small human clinical trial has demonstrated an mRNA vaccine that quickly rallies the immune system to fight ...
- New influenza vaccine strategies aim to enhance protection with T-cell responseson May 5, 2024 at 11:13 pm
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
via Bing News